• LataMed AI reported a net loss of USD 52,813 for the three months ended March 31, 2026, widening from a net loss of USD 24,455 a year earlier, while revenue was unchanged at no revenue.
• Operating expenses climbed to USD 43,384 from USD 15,967, due to additional professional fees, while other expenses edged up to USD 9,429 from USD 8,488 on higher interest expense.
• The company flagged substantial doubt about its ability to continue as a going concern, citing accumulated deficits of USD 29.65 million and a working capital deficit of USD 683,673 as of March 31, 2026.
• It acquired proprietary healthcare technology assets and IP on Feb. 17, 2026 tied to an AI-enabled healthcare analytics and services coordination platform, and organized operations through its wholly owned Venezuelan subsidiary, Inversiones Long 33, C.A.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LataMed AI Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-003348), on May 20, 2026, and is solely responsible for the information contained therein.